Abstract 3171
Background
New efficacious systemic therapies for advanced melanoma have been practice changing. More recently these therapies have been tested in the adjuvant setting for stage III disease with positive results. With recent FDA and EMA approvals for stage III disease we wished to evaluate current uptake of adjuvant therapies for stage III melanoma. Such benchmark data will be important in testing our ability to integrate clinical trial data into clinical practice.
Methods
We identified 34,376 stage III patients from the National Cancer Database (NCDB) diagnosed 2004-2015 with known extent of LN surgery and no prior invasive cancer. Use of adjuvant chemotherapy (including targeted therapy), immunotherapy and radiation therapy was assessed. Cochran-Armitage trend tests were used to test for changes in proportions over time overall and stratified by substage.
Results
Of the 34,376 patients, median age 57 years, 21,093 (61.4%) were male and 33,300 Caucasian (97.7%). The median (mean) number of positive nodes was 1 (2.1), IQR 1-2, range 1-81. Overall, 9,180 patients (27.4%) received adjuvant immunotherapy, 2,467 (7.5%) adjuvant chemotherapy and 3,088 (9.1%) adjuvant radiation. Any adjuvant therapy use declined over time from 41.9% in 2004 to 35.8% in 2015 (p < 0.001), as did immunotherapy specifically (30.6% in 2004 to 25.3% in 2015, p < 0.001). Use of any adjuvant therapy correlated with disease burden (49.9% for ≥2LN+ vs 34.6% for 1LN+, p < 0.001) and substage: Stage IIIA 33.3%, Stage IIIB 38.8%, Stage IIIC 51.7%. Use of any adjuvant therapy significantly decreased from 2004 to 2015 in both IIIA (39.9% to 22.9%) and IIIB substages (44.0% to 35.4%), each p < 0.001, while stable among Stage IIIC patients (50.6% to 52.4%, p = 0.50). Use of immunotherapy followed a similar trend (Stage IIIA 33.4% to 19.1%, p < 0.001, Stage IIIB 31.1% to 27.5%, p < 0.001, Stage IIIC 30.6% to 31.7%, p = 0.76).
Conclusions
These data provide benchmarks for adjuvant therapy uptake for stage III melanoma patients reflective of general clinical practice. Future study with integration of adjuvant systemic therapies tested in clinical trials into the general cancer population should utilize these data to test the uptake of newer adjuvant treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract